Article Text

THU0298 Consensus Definition of a Low Disease Activity State in Systemic Lupus Erythematosus
  1. C. S. Lau1,
  2. M. Nikpour2,
  3. S. V. Navarra3,
  4. W. Louthrenoo4,
  5. A. Lateef5,
  6. L. Hamijoyo6,
  7. C. S. Wahono7,
  8. S. L. Chen8,
  9. O. Jin9,
  10. A. Hoi10,
  11. E. F. Morand10,
  12. Asia-Pacific Lupus Working Group
  1. 1Department of Medicine, University of Hong Kong, Hong Kong, China
  2. 2Department of Medicine, University of Melbourne, Melbourne, Australia
  3. 3University of Santo Tomas Hospital, Manila, Philippines
  4. 4Department of Internal Medicine, Chiang Mai University, Chiang Mai, Thailand
  5. 5Department of Medicine, National University of Singapore, Singapore, -
  6. 6Department of Internal Medicine, Padjadjaran University, Bandung
  7. 7Department of Internal Medicine, Brawijaya University, Malang, Indonesia
  8. 8Department of Rheumatology, Shanghai Jiaotong University School of Medicine, Shanghai
  9. 9Department of Rheumatology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
  10. 10Department of Rheumatology, Monash Medical Centre, Melbourne, Australia


Background In systemic lupus erythematosus (SLE), organ damage, morbidity and mortality are the result of acute or sustained disease activity. The diversity of clinical features of active SLE makes quantification of disease activity problematic. The definition of a low disease activity state in rheumatoid arthritis has resulted in it being widely applied in research and clinical practice, but in SLE there is currently no such definition and thus no related outcome data. In contrast, clinicians often intuitively recognize a state of low SLE disease activity, wherein patients’ disease activity is low and treatment burden acceptable. No empirical definition of a low disease activity state in SLE has been described.

Objectives To define a ‘lupus low disease activity state’ (LLDAS), for subsequent validation using prospective cohort data.

Methods Firstly, we defined LLDAS conceptually as follows: ‘A state which, if sustained, is associated with a low likelihood of adverse outcome’, considering both disease activity and medication safety. Next, a panel of experts from Hong Kong, China, Philippines, Thailand, Singapore, Indonesia and Australia individually generated items for potential inclusion in a definition of LLDAS. These items were scored on a 5-point scale, then reduced using the Delphi method. Six experts participated in the first round of Delphi, and items with a mean score ≥ 3 were retained. Eleven experts then participated in a consensus meeting using the nominal group technique, and in a second round of Delphi, in which items with an mean score ≥ 4 were retained.

Results Fifty-six ‘unique’ items were initially generated. These fell into two domains: (i) descriptions of disease activity, and (ii) descriptions of medication use. Following two rounds of Delphi, unanimous agreement on the preliminary definition of LLDAS was reached. The final list of five items defining LLDAS comprised:

  1. SLEDAI-2K ≤4, with no SLEDAI activity in major organ systems (renal, CNS, cardiopulmonary, vasculitis, hemolytic anemia, fever) and no gastrointestinal activity);

  2. No new features of lupus disease activity compared to the previous assessment;

  3. SELENA-SLEDAI physician global assessment (PGA, scale 0-3) ≤1;

  4. Current prednisolone (or equivalent) dose ≤ 7.5 mg daily; and

  5. Well-tolerated standard maintenance doses of immunosuppressive drugs and/or approved biologic agents, excluding investigational drugs.

Conclusions We have generated a definition of LLDAS. The definition of LLDAS will be validated in a large prospective multicenter Asian-Pacific lupus cohort, using outcomes including organ damage and death, and refined in response to subsequent findings. Once validated, LLDAS may serve alone, or in combination with variables such as patient reported outcomes, as a treatment target in SLE clinical practice, research, and clinical trials.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.